Seventh International Congress of Human Genetics* Molecular genetics
The Berlin International Congress on Human Genetics was one of those large (2000 strong) meetings we all hate and, considering that, was far better than most. With several hundred posters and frequent simultaneous sessions (plus old friends with whom it was both pleasant and useful to talk), the following notes on molecular biology advances are of necessity idiosyncratic to the extreme. I missed several important papers for sure. Still, here are a few impressions.
Most geneticists will know that the 'gap' between the physical and genetic maps is now receiving a great deal of attention. Hans Lehrach (EMBL) organised a very interesting session looking at techniques which could analyse lengths of the human genome larger than clones (that is, more than 50 000 base pairs) and smaller than centiMorgans (1 cM is approximately equal to one million base pairs or one megabase [mbl). These include pulse field gel electrophoresis, which uses restriction enzymes cleaving DNA very rarely to produce large fragments. These can be separated using alternate pulses, each running for some seconds, at angles across an agarose gel. Fragments ranging from 100 kb to 5 mb can be separated and hybridised to gene specific probes. Margit Burmeister (EMBL), Kay Davies (Oxford), and Gert-Jan van Ommen (Leiden) all presented exciting data showing how this technique can be used to study the region surrounding the Duchenne muscular dystrophy locus. Anna-Maria Poustka (EMBL) presented another technique, using junction fragments containing rare cutters for mapping megabase regions, and it was apparent that the two techniques together would permit maps and jumps to be made for megabase regions remaining after linkage mapping ceases to produce new data.
Conrad Gilliam (Boston) presented similar data for the region of chromosome 4 including the locus for Huntington's disease, and announced a new probe, C4H, which is closer to HD than G8. HD has been rather intractable; having been very lucky to achieve a linkage soon after starting to run probes through families, the Boston group has found the disease locus to be so telomeric that flanking markers could not be identified. It is still not clear whether C4H is flanking, but it is certainly closer. *Reports on other sections of this Congress will appear in future issues of the Journal.
Similarly, Martin Farrall and I (St Mary's Hospital, London) gave an update oel DNA linkage to cystic fibrosis, reporting the new probes and orders, and Martin Farrall was able to give a list of almost 150 first trimester prenatal diagnoses in Europe using the closest probes, pJ3-11, met, 7C22, and 79a.
Several new mapping exercises were reported, the most extensive by Gordon Stewart, formerly of Glasgow and now working in Boston. He has a large number of linked markers from top to bottom of chromosome 21. It is obvious that it will be only a matter of a year or two before the map is completely filled in, at least for the smaller chromosomes, and sequencing will begin. However, from the practical point of view, it is apparent (as noted by Victor McKusick in his usual comprehensive overview) that enough markers now exist to map any locus onto a human chromosome unequivocally, if with consider-. able effort.
New resources abound. Most geneticists know of CEPH, which provides DNA from large families for pedigree studies, and of the Los Alamos/Livermore chromosome specific human gene libraries. The ATCC is now providing human recombinants in bacteria for a small service fee, which should prove extremely useful. Henry Ehrlich (Cetus) reported a neat technique which allows one to amplify any gene sequence which is defined between known markers, using a thermophilic DNA polymerase with primers. It gives so much DNA after a few cycles that it may render diagnostic blotting with radioactive probes unnecessary.
Several of the best papers drew on experience over several years. Sergio Ottolenghi (Milan) summarised the data for cis mutations which alter expression in the human globin supergene family, and thus change the severity of the thalassaemias, and Bob Weinberg (Boston) gave data on human oncogenes before describing a most exciting isolation of a putative cDNA sequence which appears to be the primary genetic cause of retinoblastoma, localised on human chromosome 13ql3/14. This appeared to involve a measure of luck, since the clone, although known to be localised to the right region of chromosome 13, was not selected because it coded for a relevant protein.
However, I found the most exciting reports were those which pointed the way to gene therapy. Many of us have felt that somatic gene therapy is a long 123 way off, while germ line therapy was unlikely ever to arise. I am now convinced that we are wrong. Tom Caskey (Houston) and others presented convincing data to show that retrovirus based (but disabled) vectors could introduce active human genes into marrow and liver cells at high efficiency, a prerequisite to the treatment of the severe combined immunodeficiency disorders. Oliver Smithies (Wisconsin) presented even more exciting data, proving site specific integration of f globin genes into cells in culture. These experiments have, to date, only succeeded in adding a gene at the 'right place', the defective gene is still present. Most interesting was his proposal that it should also be possible, using modified 'omega vectors', to replace a defective gene in a site specific manner with a normal one. It could even be possible to do this during early embryogenesis. The certainty of somatic gene therapy for severe diseases was apparent.
There was lots more, of which I just want to mention one poster. It was shown that high molecular weight DNA samples, suitable for Southern blotting, could be obtained from dried heel prick blood on Guthrie cards. So please, don't throw away your old Guthrie cards with their spare blood spots, they could be an absolutely invaluable resource for molecular genetics.
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Satellite meeting: Alphafetoprotein in diagnosis and screening
A full day's meeting devoted to a fetoprotein (AFP) diagnosis and screening, with 25 presented papers, is a daunting prospect. Amniotic fluid and maternall serum AFP assays have been in fairly routine use for over a decade. Even the newcomer, acetylcholinesterase, was first reported in 1978. Nevertheless, the success of AFP screening in reducing the birth prevalence of neural tube defects, as well as the opportunities that it presents as an additional mode for prevention of Down's syndrome births, should keep the subject in view of all those concerned with reduction in incidence of serious birth defects. Several papers presented data on AFP screening in countries where it is still an infant programme:
Hungary (J Szabo), Switzerland (P Grob), Israel (R Shomrat), and Finland (M Rynnanien), in the last named the target being congenital nephrosis rather than neural tube defects. In some areas pilot programmes on research funds have not been translated into routine service, the problems being econiomic and political rather than technical. The potential of maternal scrum AFP assay as one of the best general indicators of high risk premlancies W\ls documented by Burton (USA), Ferguson-Smith (UK), Szabo (Hungary), and Legum (Israel). The point was made repeatedly, as it has been made many times before, that such screeningo has value even in localities with a comparatively low incidence of neural tube defects.
This theme was amplified by the emerging data on the relationship between low maternal AFP and Down's syndrome. The most comprehensive programmes have been run in the United States (Burton, Crandall, Greenberg), though there were also reports from Denmark (Norgaard-Pedersen), Finland (Rynnanen), and Germany (Voigtlander).
There is now little doubt that a comiibinationi of screening by maternal age and low scrumii AFP is more effective than by maternal age alone in detecting Down's syndrome fetuses. But whether and how cytogenetics laboratories can cope with the extra load of amniotic fluid samples is an unresolved issue. The scientifically respectable solution of karyotyping amniotic fluid sa.mples where the primary indication is low serum AFP, and not where the indication is high serum AFP, appears to be unacceptable to most obstetricians, either for legal (USA) or social/emotional (rest of the world) reasons.
When a chorionic villus sample (CVS) is taken there is often a rise in maternal serum AFP levels 'within 24 hours. There is a possibility that the magnitude of this rise may have proggnostic value for the pregnancy. Szabo (Hungary) and Fuhrmlann (Germany) both presented data suggesting that a doubling of the serum AFP value over the pre-CVS level was quite a potent indicator of impending fetal loss. Both series were small and will need confirmation, as will the intriguing suggestion by Milunskv (USA) that a very low pre-CVS maternal AFP may signal a chromosome abnormality.
The last session of the day concluded with a review by Ferguson-Smith (UK) of the impact of maternal serum AFP screening on the incidence of neural tube defects in the community. The West of Scotland programme, covering, 1976 to 1985, has screened 22t) ()()( pregnancies to datte and must be the largest of this type attempted. By careful analysis of live births, stillbirths, and terminations, Ferguson-Smith was able to conclude that they had reduced the birth incidence of neural tube defects by 74%. No other prenatal screening progriamme can claim figures anywhere ne'ar this. D J H BROCK H1iocnan Genietics Uniit, Western Geeneral Hospital.
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